Chemical Industry

A French pharmaceutical company active in the development and commercialisation of sterile injectable medicines has established a fully operational US commercial entity designed to market pharmaceutical products throughout the United States. Following a strategic reorganisation of its international commercial activities, the company has decided to make this US operating platform available to a European biotechnology or pharmaceutical partner wishing to accelerate its US market entry. The offered infrastructure includes: • 36 active pharmaceutical state licences covering the commercialisation of medicinal products across the US regulatory landscape; • established operating agreements with specialised third-party logistics providers, regulatory service providers and government pricing management services; • a fully operational virtual manufacturer structure enabling rapid product commercialisation; • two operational office locations; • deferred tax assets representing future tax savings. The existing licensing infrastructure allows immediate commercial operations for products covered by the current regulatory framework without requiring a complete state-by-state licensing process. Building an equivalent infrastructure would normally require considerable regulatory effort, significant legal expenditure and approximately 12 to 18 months before commercial readiness. The company is seeking European biotech or pharmaceutical organisations wishing to commercialise products in the United States. Cooperation may take the form of a commercial agreement granting access to the existing commercial infrastructure or an investment agreement involving the acquisition of the US commercial entity and its associated assets. The objective is to enable the partner to substantially reduce regulatory preparation time and accelerate US market access. Advantages and innovations: The proposed commercial platform offers several significant competitive advantages: • Existing multi-state pharmaceutical licensing infrastructure covering the regulatory requirements for commercial operations across the United States. • Estimated reduction of 12–18 months in market entry compared with establishing a new US commercial entity. • Avoidance of more than USD 1 million in legal and regulatory establishment costs. • Operational contracts already in place with logistics, compliance and government pricing service providers. • Licences maintained through an established compliance programme with relatively low annual maintenance costs. • Deferred tax assets providing future tax optimisation opportunities. • Infrastructure suitable for multiple pharmaceutical products, as licences are attached to the legal entity rather than individual products. Expected role of a partner: The partner is expected to be a European biotechnology or pharmaceutical company with products intended for commercialisation in the United States. The partner should leverage the existing US licensing and commercial infrastructure to accelerate market entry while managing the commercialisation of its own product portfolio.